The Australian Research Data Commons (ARDC) invites you to participate in a short survey about your
interaction with the ARDC and use of our national research infrastructure and services. The survey will take
approximately 5 minutes and is anonymous. It’s open to anyone who uses our digital research infrastructure
services including Reasearch Link Australia.
We will use the information you provide to improve the national research infrastructure and services we
deliver and to report on user satisfaction to the Australian Government’s National Collaborative Research
Infrastructure Strategy (NCRIS) program.
Please take a few minutes to provide your input. The survey closes COB Friday 29 May 2026.
Complete the 5 min survey now by clicking on the link below.
Outcomes Of Treatment Decisions And Prediction Of Individual Treatment Response In Multiple Sclerosis
Funder
National Health and Medical Research Council
Funding Amount
$92,358.00
Summary
Multiple sclerosis is the most common cause of neurological disability among young people. With the increasing choice of therapies, the goal of freedom from disease has become more realistic. We will use the MSBase international multiple sclerosis registry to identify optimal, individually-tailored therapeutic strategies. We will also implement volumetric magnetic resonance imaging in routine practice, thus translating a research tool into an instrument available to patients and their doctors.
Validating Novel Serum Markers Of Neurodegeneration In Multiple Sclerosis Patients.
Funder
National Health and Medical Research Council
Funding Amount
$516,304.00
Summary
In multiple sclerosis (MS), permanent disability occurs when brain cells known as neurons are damaged following an immune attack. Current treatments reduce the number and severity of immune attacks, but they do not prevent neuron damage or permanent disability in many patients. There is currently no direct way to measure neuron damage in humans, so it is difficult to develop new drugs to prevent it. To address this need, we will trial a new blood test for measuring neuron damage in MS patients.
Objectively Monitoring Neurodegenerative Disease Progression: Speech As A Clinical Marker
Funder
National Health and Medical Research Council
Funding Amount
$302,123.00
Summary
It is difficult to monitor disease progression in some neurodegenerative disorders like Huntington’s disease or types of dementia without using expensive and invasive assessment techniques. Yet, by repeatedly recording and analysing the speech (how we speak, not what we say) of a patient, we build up a picture of how the brain is functioning and changing over time. This will lead to a more personalized approach with more effective treatments being given to the right patients at the right time.
Stroke is a devastating disease affecting 50,000 Australians and over 5 million people globally every year. The overall aims are to develop better knowledge, better tools and more effective strategies to treat and prevent stroke. Projects include discovery of new genetic stroke risk factors, better management of recognised risk factors, trials of treatment strategies for acute stroke, and the investigation of strategies for more effective implementation of treatments.
ALS4 Mice Show TDP-43 Protein Mislocalization In Motor Neurons Characteristic Of Sporadic ALS Patients; Suggesting This Model Is Likely To Reveal Important Patho-mechanistic Disease Insights
Funder
National Health and Medical Research Council
Funding Amount
$108,466.00
Summary
SETX gene mutations cause an inherited motor neurone disease (MND) known as ALS4. Our current understanding of MND was revolutionized by the discovery that a protein known as TDP-43 is the main component of protein accumulations found in dying human motor neurones. We have generated a unique mouse model of ALS disease that will be useful for research purposes, but may also prove effective for drug testing.